Drugs / Inobrodib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04068597 | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03568656 | Jul 2018 → Jul 2025 | breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma | CellCentric Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07096778 | Jan 2026 → Dec 2029 expected | plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inobrodib | “Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies” NCT04068597 ↗ |
| Known as | CCS1477 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03568656 ↗ |
| Modality | Small molecule | — CHEMBL4785363 ↗ |
| Route | Oral | “Capsules, oral” NCT03568656 ↗ |